Clinical Data Presented at the 66th Annual Meeting of the American Academy
FREEPORT, N.Y., Feb. 11 /PRNewswire/ -- AGI Dermatics presented clinical research that indicates the 8-oxo-guanine DNA glycosylase (OGG1) encapsulated in liposomes is an effective agent in treating photodamaged skin by enhancing DNA repair, reducing MMP-1 secretion and increasing collagen production in UV irradiated skin cells. The data was presented in two scientific posters at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio.
"The development of effective skin protection against photoaging and even skin cancer requires detailed understanding of the underlying molecular mechanisms of the skin, a belief that is at the core of all our research," said Daniel Yarosh, PhD, President, AGI Dermatics. "These studies demonstrate that OGG1 encapsulated in liposomes has a profound effect on repairing the cellular damage that is caused by the sun and other environmental stressors. It's a first step to understanding and reversing symptoms of premature skin aging."
The first study examined the question whether OGG1 can repair the nuclear and mitochondrial oxidative damage caused by the irradiation with solar stimulating UV (ssUV) of sub-confluent normal human epidermal keratinocytes (NHEK).
For the test, sub-confluent NHEK were irradiated with ssUV to induce the intrinsic apoptotic pathway, as determined by the activation of the initiator caspase-9 in a dose-dependent manner. Following irradiation, the keratinocytes were treated with OGG1 for up to 24 hours. The study then looked at the results of the OGGI on caspase-9 activation following ssUV irradiation of sub- confluent NHEK.
The treatment of ssUV stimulated NHEK showed that ssUV induced less than two-fold caspase-9 activation, and that OGG1 does not have significant effects on caspase-9 levels in ssUV irradiated cells. Accordingly, this indicates that confluent NHEK treated with OGG1 are resistant to ssUV cell death, allowing more time for DNA repair.
The second study examined the question of whether repairing the ssUV- induced DNA damage by OGG1 in the epidermal keratinocytes, would also present the by-stander effect in the fibroblasts by reducing the release of TNf-a from NHEK. For the test, dermal fibroblasts were grown for 48 hours in materials taken from the ssUV-irradiated NHEK. The ssUV-irradiated NHEK induced more MMP-1 secretion and greater collagen loss compared to direction irradiation of NHDF with the same ssUV dose. The model system was also used to investigate whether OGG1 would be effective in diminishing the detrimental effects of ssUV radiation on the underlying dermis. Treatment of ssUV-irradiated NHEK with OGG1 liposomes for 24 hours suppressed the induction of MMP-1 secretion by NHDF, as well as showed diminished collagen loss.
In conclusion, these results indicate that treatment of dermal fibroblasts and epidermal keratinocytes with OGG1 liposomes enhance DNA repair, reduces MMP-1 and increases collagen levels in the epidermis and the underlying dermis.
AGI Dermatics is the developer of Remergent, a doctor-dispensed skincare line based on the science of DNA repair. Remergent DNA Repair Formula and Antioxidant Refoliator both contain Roxomes, liposomes encapsulating OGG1.
About AGI Dermatics
AGI Dermatics is the bio-pharmaceutical laboratory that has led research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell- signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. http://www.agiderm.com
|SOURCE AGI Dermatics|
Copyright©2008 PR Newswire.
All rights reserved